StemCell Therapy

Vancouver, British Columbia, Canada - TheNewswire - October 5, 2020 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP) , FSE: 2FA, (OTC:FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced that it has signed a Memorandum of Understanding ("MOU") with Purity-IQ Incorporated of Canada ("Purity-IQ") (http://purity-iq.com/) to integrate the Purity-IQ Cannabis Authenticity and Purity Standard (CAPS) and its Fingerprint(TM) technology with the GCAC efficacy platform; with a focus on the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA$4.1 billion in 20211.

Following on from its TraceLocker announcement on September 3rd, GCAC is attracting key players in the Canadian medical cannabis space. The company's MOU with Purity-IQ is a significant endorsement of the GCAC blockchain compliance and medical efficacy data collection platform. The proposed cooperation integrates GCAC's efficacy-data with Purity-IQ's CAPS Fingerprint(TM) service, a unique genetic and chemical profile of cannabis cultivars.

GCAC's blockchain medical efficacy smartphone app immutably links a specific Purity-IQ CAPS Fingerprint(TM) cultivar directly to a consumer's anonymous efficacy attestations. This is set to revolutionize the traceability of cannabis efficacy and bring it more in line with formal medical-trial information that a traditional dispensing pharmacist would be able to reference.

Purity-IQ can uniquely identify a cultivar based on a metabolite profile using Nuclear Magnetic Resonance (NMR) and DNA chip bioinformatics. The intent is for Purity-IQ Fingerprints to be referenced by GCAC's efficacy platform to verify 'batch-to-batch' consistency in medical cannabis efficacy programs.

GCAC's CEO, Brad Moore "I have no doubt that our smartphone efficacy-data platform is an industry leader for cannabis. Bringing the Purity-IQ scientific fingerprinting of cannabis cultivars, to which our consumers will report their efficacy, really builds a picture of what works for a consumer and what doesn't. This is where medical cannabis needs to get to and, we're bringing it there!"

Brad Moore continued, "With our blockchain truths and efficacy data-sets, medical practitioners, pharmacists, cultivators and processors gain efficacy data previously only found in formal drug trials. We change that and bring the wisdom-of-the-crowd to bear for medical cannabis efficacy."

Under the agreement, GCAC contributions regarding efficacy are the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with, GCAC's medical cannabis solutions, and this is what the company believes makes GCAC one of the most exciting efficacy platforms in the cannabis and RegTech space.

1 https://www.yahoo.com/news/which-pot-stocks-will-survive-cannabis-bankruptcy-risk-131732204.html

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world's first end-to-end - from patient to regulator - medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and GCAC smart rewards to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Driven by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more Company information, please visit http://www.cannappscorp.com, or review its profiles on http://www.sedar.com and on the Canadian Securities Exchange's website (www.thecse.com).

Purity-IQ IncorporatedPurity-IQ is a Canadian biotechnology company based in Mississauga, Ontario. It is committed to innovation in research and development and in the commercialization of practical and affordable validated quality assurance standards and tools, designed to further support brand product claims related to identity, authenticity, and purity. Purity-IQ focuses on commodities and inputs for the food, drug, beverage, natural health products and cannabis industries.

To schedule an interview, please contact: For more information, please contact:

Bradley Moore Corporate Communications

Chief Executive Officer Telephone: +1 (800) 409-5679

Email: bmoore@cannappscorp.com Email: info@cannappscorp.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

See the original post here:
GCAC Strengthens Its Medical Cannabis Efficacy Platform with Purity-IQ Biotechnology to Address a $4.1 Billion Market Opportunity - TheNewswire.ca

The agricultural biotechnologybusiness is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.

The major players covered in the agricultural biotechnology market report areKWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Inquiry For Customize Report With Discount Athttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

Insights of the Study

Global Agricultural Biotechnology Market Drivers & Restraints :

To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

See the rest here:
Covid-19 Update:Agricultural Biotechnology Market 2020||To Witness The Highest Growth Globally In Coming Years || MITSUI & CO., LTD., AgPlenus...

The Coalition of Epidemic Preparedness for Innovation (CEPI), a global initiative to develop vaccines against emerging epidemics, has named Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology (DBT), as part of the Global Network of Laboratories for centralized assessment of Covid-19 vaccine candidates that are under development.

The Faridabad-based laboratory, under DBT, is one of the six laboratories that have been recognised by the CEPI. The CEPI network will initially involve six labs - one each in Canada, Britain, Italy, the Netherlands, Bangladesh and India, for the assessment of Covid-19 vaccine development.

Under the CEPI Global network, all the laboratories will use the same reagents and follow a common set of protocols to measure the immune response of multiple vaccine candidates under development and trial.

The Department of Biotechnology, Government of India, is supporting efforts for Covid-19 vaccine development and testing. THSTI runs comparability studies with other laboratories internationally and will form an important part of the global network, said DBT Secretary Renu Swarup.

We are very pleased that the bioassay laboratory at Translational Health Science and Technology Institute, an autonomous institute of Department of Biotechnology, has been identified by CEPI for centralised immunoassay analysis for COVID 19 vaccines under development globally. It is well-positioned to run comparability studies with other laboratories internationally and will form an important part of the global network. This is another excellent example of Ind CEPI and CEPI partnership, Swarup added.

Read the original:
Department of Biotechnology lab to be part of global Covid-19 vaccine assessment project - ETHealthworld.com

Food Biotechnology Market research Report is an inestimable supply of perceptive information for business strategists. This Food Biotechnology Market study provides comprehensive data which enlarge the understanding, scope and application of this report.

A specific study of competitive landscape of the global Food Biotechnology Market has granted, providing insights into the corporate profiles, financial standing, recent developments, mergers and acquisitions, and therefore the SWOT analysis. This analysis report will provides a transparent program to readers concern regarding the overall market situation to further choose on this market projects.

The Food Biotechnology Market report profiles the successive companies, which includes: ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies

Get Sample Copy of this Report @ https://www.reportsintellect.com/sample-request/1314522

This report studies the global Food Biotechnology Market status and forecast, categorizes the global Food Biotechnology Market size (value & volume), revenue (Million USD), product price by manufacturers, type, application, and region. Food Biotechnology Market Report by Material, Application and Geography with Global Forecast to 2025 is an connoisseur and extensive research provide details associated with worlds major provincial economic situations, Concentrating on the principle districts (North America, South America Europe, and Asia-Pacific) and the crucial nations (US, Germany, UK, Japan, South Korea, and China).

Reports Intellect analysts are currently working analyzing and integrating their insights on the effect of COVID-19 across diverse industry verticals. These insights are quite promising for different businesses and industries to cope up with this unprecedented downturn and take effective strategic decisions to thrive and proliferate within competitive business ecosystem.

By Types: Transgenic CropsSynthetic Biology Derived Products

By Applications:AnimalsPlants

Market Segment by Regions, regional analysis coversNorth AmericaEuropeAsia-PacificSouth AmericaMiddle East and Africa

Table of Contents

Global Food Biotechnology Market Size, Status and Forecast 20251 Market Overview2 Manufacturers Profiles3 Global Food Biotechnology Sales, Revenue, Market Share andCompetitionby Manufacturer4 Global Food Biotechnology Market Analysis by Various Regions5 North America Food Biotechnology by Countries6 Europe Food Biotechnology by Countries7 Asia-Pacific Food Biotechnology by Countries8 South America Food Biotechnology by Countries9 Middle East and Africas Food Biotechnology by Countries10 Global Food Biotechnology Market Segment by Types11 Global Food Biotechnology Market Segment by Applications12 Food Biotechnology Market Forecast13 Sales Channel, Distributors, Traders and Dealers14 Research Findings and Conclusion15 Appendix

Get a Good Amount of Discount on this report @ https://www.reportsintellect.com/discount-request/1314522

Overview of the chapters analysing the global Food Biotechnology Market in detail:

Reasons why you should buy this report

About Us:-Reports Intellect is your one-stop solution for everythingrelating market researchand market intelligence.

Our team works hard to fetchthe best authentic research reports backed with impeccable data figures that guarantee outstanding resultsanytimefor you.

So, whetheritsthe most recentreport from the researchers or a custom requirement, our team is hereto helpyou within absolute bestmanner.

Contact Us:

[emailprotected]PH + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Read more here:
Food Biotechnology Market Laminar Growth to be witnessed by 2025 & Analysis by ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were published in Clinical Breast Cancer. The manuscript appears in the October 5, 2020 online issue accessible at https://www.clinical-breast-cancer.com/article/S1526-8209(20)30258-5/fulltext.

ExteNET was a multicenter, randomized, double-blind, Phase III trial of 2,840 HER2-positive eBC patients who received neratinib after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab. Patients were stratified by hormone receptor status and randomly assigned to one year of treatment with either oral neratinib 240 mg/day or placebo. The primary endpoint of the trial was invasive disease-free survival (iDFS) with overall survival as a key secondary endpoint. Within the European Union, neratinib is approved in patients with HR+ breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab containing regimen.

The manuscript presents data focusing on HR+ patients who initiated treatment within a year of completing an adjuvant trastuzumab containing treatment (HR+ /< 1 yr) and subgroups of clinical interest including patients who did not achieve a pathological complete response (no pCR) after neoadjuvant treatment and therefore were at a high risk of disease recurrence. (HR+/ <1 yr, no pCR)

In the HR+ /< 1 yr patient population, the absolute 5-year invasive disease-free survival benefit versus placebo was 5.1% (HR=0.58, 95% CI 0.410.82) and absolute 8-year overall survival benefit was 2.1%. (HR=0.79, 95% CI 0.551.13). The 5-year cumulative incidence of CNS metastases was 0.7% in the neratinib arm and 2.1% in the placebo arm.

In the HR+/ <1 yr, no pCR subgroup of patients that were at a high risk of disease recurrence the absolute 5-year iDFS benefit in the neratinib arm versus placebo was 7.4% (HR=0.60; 95% CI 0.331.07) and the 8-year overall survival benefit was 9.1% (HR=0.47; 95% CI 0.230.92).

Most common grade 3 adverse events were diarrhea (39% vs placebo, 1%; without mandatory anti-diarrheal prophylaxis), vomiting (4% vs <1%), and fatigue (2% vs <1%).

Professor Arlene Chan, Vice Chair Breast Cancer Research Centre WA, said, Deciding on which patients benefit most from a given therapy is an important goal for clinicians. This newly published study provides consistent and durable benefits of neratinib in a subset of HER2-positive early stage breast cancer patients who are considered to be at greater risk of relapse: namely patients with HR+ tumors that did not achieve a pCR after neoadjuvant treatment (no pCR). The benefits demonstrated are meaningful in all endpoints evaluated, including iDFS, OS and CNS recurrence, and thus should help guide future clinical decisions.

Hope S. Rugo, MD, Professor of Medicine, University of California San Francisco Comprehensive Cancer Center, said, HER2-positive HR+ patients who do not achieve a pCR are at increased risk of recurrence, even after receiving current standard of care treatment. In a descriptive subset analysis, extended adjuvant therapy with neratinib demonstrated a positive benefit in these patients not only in iDFS, but also in OS. In addition, the trend toward lower CNS involvement is a very important consideration, given the profound impact of CNS metastasis on future prognosis. These data coupled with the recently published data from the CONTROL study, which shows improved tolerability with dose escalation, should allow more patients to benefit from this important therapy.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, Although there have been many new treatment options for patients with early stage HER2-positive breast cancer, the risk of disease recurrence remains significant and more must be done. These newly published data demonstrate that neratinib provides a clinically meaningful reduction in the risk of recurrence and provides a very important option for these high risk patients.

About HER2-Positive Breast Cancer

Up to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease) and in the ExteNET study, 57% of patients were found to have tumors that were hormone-receptor positive. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer recurring, up to 25% of patients treated with trastuzumab experience recurrence within 10 years, the majority of which are metastatic recurrences.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

See the original post:
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone...

The National Institutes of Health (NIH) has awarded $1.48 million to the Tuskegee University College of Veterinary Medicine for breast cancer research. Deepa Bedi, is an associate professor in the Department of Biomedical Sciences and is the principal investigator for the four-year program entitled, Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer. Bedi will evaluate the role of the protein in the progression of breast cancer.

I aim to use this protein as a marker of TNBC progression as well as a target to deliver anti-cancer drugs to this highly aggressive and metastatic cancer. This grant will provide the necessary resources to fulfill this hypothesis and be able to contribute to the knowledge and cure of TNBC, particularly in African American women, Bedi said.

We are proud of the contributions that Bedi will make to biomedical research as she translates the discoveries and observations into therapies in her cancer laboratory in the college, said Dr. Ruby Perry, dean of the College of Veterinary Medicine. The data and information gained from this newly funded research study will heighten awareness and enhance the cancer research program here at Tuskegee University.

We are also appreciative to Dr. Shaik Jeelani, vice president for research and dean of the graduate school, for his support of our faculty and their pursuits of research studies that are relevant to animal and human health, Perry said. Biomedical research, in particular breast cancer, is one of our signature research programs here at the university.

Bedis work in cancer research was previously funded by a $441,000 three-year NIH grant in 2016. She coordinates many efforts across campus with Dr. Clayton Yates, director of the Center for Cancer Research at Tuskegee University.

Previously, using phage display technology in Bedis cancer biomarker discovery and therapeutics lab, she discovered heat shock protein 60 to be highly expressed, and to have a higher expression in Blacks with breast cancer as compared to white Americans.

The U.S. National Library of Medicine says breast cancer is one of the most frequently diagnosed cancers and the leading global cause of cancer death in women, accounting for 23% of cancer diagnoses 1.38 million women and 14% of cancer deaths 458,000 women each year. Triple-negative breast cancers occur in 10% to 15% of patients, yet this disease subtype accounts for almost half of all breast cancer deaths and represents a highly aggressive and metastatic phenotype, specifically among Black women.

Read the original here:
NIH awards $1.48 million grant to Tuskegee University for breast cancer research - Alabama NewsCenter

Taking the lead on a five-year, $100 million federal program, Tufts University will head a wide-ranging international development and research effort to head off future pandemics like COVID-19, which has killed more than one million people and devastated economies around the world.

Experts from several Tufts schools and 12 partner institutions will take part in the project, which was announced by the United States Agency for International Development (USAID) on Sept. 30. They will work with high-risk countries to strengthen their capacity to gain and use essential knowledge about how viruses emerge; collaborate with them to identify human behaviors that lead to outbreaks; and help them prepare their public health systems to contain spread during a pandemic.

The project, named Strategies to Prevent Spillover, or STOP Spillover, will target viral zoonotic diseases infections that originate in animals before they spillover into humans, sometimes with terrifying consequences. There are signs that the SARS-CoV-2 coronavirus may have originated in bats, as did the SARS and MERS viruses in the early 2000s. Ebola most likely originated in bats or primates. Scientists believe people first contracted HIV by hunting and eating chimpanzees. An estimated 70 percent of emerging infectious diseases are zoonotic, and outbreaks are getting more frequent.

Over the last five years alone, more pandemics have emerged than in the previous 15 years, said Saul Tzipori, distinguished professor of microbiology and infectious diseases and Agnes Varis University Chair in Science and Society at Cummings School of Veterinary Medicine.

Some parts of the world are more susceptible to spillover, said Tzipori, who will be a lead researcher on the project. Rural areas where people live near wildlife are more likely to see diseases transfer through infected food and shared drinking and bathing water. Farms and markets that keep domestic and wild animals in close proximity heighten the risk of a virus or other pathogen jumping between species, as does hunting bats, monkeys, pangolins, civets, and other game known as bushmeat.

Its the projects focus on what people can do differently in their daily routines to stop infectious diseases that makes program director Deborah Kochevar, a senior fellow at the Fletcher School of Law and Diplomacy, believe it can succeed.

This project builds on the work of USAIDs Emerging Pandemic Threats program to understand dynamic infectious disease interfaces among animals, people, and the environment, said Kochevar, dean emerita and former Henry and Lois Foster Professor at Cummings School of Veterinary Medicine. Tufts veterinary and medical school faculty have contributed extensively to the EPT program over the past ten years. STOP Spillover broadens our interdisciplinary and interprofessional involvement to include veterinary, medical, nutrition, engineering, and global health diplomacy expertise.

With that in mind, the project will work with 10 nations in Africa and Asia to create country-specific plans for sharing knowledge about emerging pathogens, reducing risks, and responding rapidly should outbreaks happen.

One aim is to empower local expertise in those countries and strengthen their capacity to gain critical knowledge about how viruses emerge, and to refine and use that knowledge effectively, efficiently, and sustainably to reduce the risk of zoonotic viral spillover and spread, said Hellen Amuguni, an associate professor at Cummings School.

Infectious disease experts at Cummings School, known internationally for its contributions to the successful campaign to eradicate the livestock disease rinderpest, will play a key role. Cummings School faculty on the EPT program, led by Tzipori and working with the University of Minnesota, supported the establishment of two university networks comprising dozens of institutions in Asia and Africa. These two networks, Africa One Health University Network (AFROHUN) and Southeast Asia One Health University Network (SEAOHUN), educate and train students and graduates in pandemic preparedness. These networks are essential partners and played important roles in securing the current project.

Having the university networks on the ground, helping to lead this effort, understanding the local situation, understanding the issuesthat's really, really important for us, Amuguni said.

In fact, the project will work from the ground up, with the countries themselves helping to decide what gaps need to be filled, be it better health communications or testing technologies. Ideally, the countries will collaborate with each other directly and share expertise.

We want to walk away at the end of five years having helped to build the capacity of these countries to recognize these pathogens, to be able to respond to them, and should they break out, to ameliorate them, said Jeffrey Griffiths, a professor at the School of Medicine who is well versed in human, animal, and environmental epidemiology.

Although Tufts has strong health-science expertise, its constellation of schools offers more than a microbiologists view of infectious diseases, said Caroline Genco, vice provost for research. And that, she suspects, is what made Tufts proposal distinctive. The call is a little different, she said. It has to do with policy, on-the-ground work in the community, and civic engagement. Thats what Tufts is great at. We have diversity in how we look at this.

At the School of Engineering, Associate Professor Daniele Lantagne brings a body of research on water, sanitation, and disease outbreaks in low-income countries. Meanwhile, team members from the Friedman School of Nutrition Science and Policy, the Feinstein International Center, and the Fletcher School of Law and Diplomacy will bring relationships with international public- health programs and experience with complex emergencies.

The Broad Institute, one of the project partners and an expert on viral genomics, will be working with Tufts to adapt its diagnostic tools for use in this project. But STOP Spillover will involve far more than testing wildlife for pathogens. The goal is to look holistically at the entire spillover ecosystem, taking into account the cultural, economic, political, and environmental factors that make viral spillover and spread likely.

One investigative path will be figuring out why people eat certain wild animalsis it culturally important or just whats available or affordable?and then devising ways to change those behaviors.

Many people think that the solution is as simple as shutting down wildlife farms or markets, Amuguni said. But these markets and farms are a source of livelihood for people.

Griffiths agreed. People are engaged in these behaviors because it allows them to survive, he said. What you want to do is figure out how to get around it.

In some cases, the solutions are as much in the realm of economics as in the biological sciences, said Patrick Webb, Alexander MacFarlane Professor at the Friedman School. What foods do people buy? Why do they spend on that instead of something else? And what are the economic incentives that we can put in place to change those decisions?

Governments, for example, could enact policies that make other forms of meat, eggs or other nutrient-rich foods cheaper than bushmeat.

Ecology, too, plays a large role in pandemic risks. Deforestation can force wildlife to move closer to humans, increasing the chances of a disease spillover. At the same time, more frequent droughts in countries such as Uganda have prompted farmers there to cultivate more acreagesometimes encroaching on wildlife habitatsin a bid to salvage some crops should others fail.

Vulnerable farmers often push farther and farther into the forest margins, just to try and have an insurance policy by expanding the land area that they cultivate, Webb said.

Here, the solutions could be technological: Farmers might change that practice if they have access to better seeds, better markets, and better irrigation.

The project will look at how spillover is influenced by pollution, climate changeeven gender. (Hunters are typically men, but women are often responsible for the nutrition and health of a household.)

Tufts scientists have long recognized that human, animal, and environmental health are interconnecteda concept known as One Health. The shocking consequences of the COVID-19 pandemic have driven that message home.

If we disrupt animal life cycles, we may be inviting their pathogens to come on over and join our human families, Kochevar said. Humans need to be thoughtful about the impact they have on other living things. We need to appreciate that our human health depends upon the health of other creatures and the integrity of our shared ecosystems.

Julie Flaherty can be reached at julie.flaherty@tufts.edu. Top photo: Neil Brandvold, Creative Commons license.

Read more:
A Push to Prevent the Next Pandemic - Tufts Now

SACRAMENTO (CBS13) A new partnership is working to save wildlife that has been injured in Californias wildfires.

The Wildlife Disaster Network is a partnership between veterinarians at UC Davis and the California Department of Fish and Wildlife, along with many volunteers. The goal is to send in search and rescue teams to find and treat animals.

So far, they have had their work cut out for them, treating injured bears, mountain lions, coyotes, and more. Many of them are suffering from severe burns and are on long roads to recovery.

With wildlife, you certainly have a few more challenges than you would taking care of your dog or cat. One of them is when they want to take off a bandage theyre pretty much going to take off the bandage. So you have to be creative, Jamie Peyton, with the UC Davis School of Veterinary Medicine, said.

READ:Pets Burned In Camp Fire Healing With Fish Skin Bandages

That creativity involves special bandages made of fish skin that are OK for the animals to chew.

On Monday, crews were able to release a recovered bear back into the wild, which is the goal for all of the animals they work with.

The Wildlife Disaster Network says one of the keys to their process is having the public report injured wildlife to them. They have established a hotline 1-800-WHC-OIL-9 (1-800-942-6459) for first responders, utility workers and the general public to call in for assistance with coordinating care for injured wildlife.

Go here to read the rest:
Wildlife Disaster Network Treats Animals Burned In Wildfires - CBS Sacramento

BETHLEHEM, Pa. (WLVT) - Mans best friend is sniffing out one of Pennsylvanias biggest agricultural threats.

"For us it was literally, can the dogs be trained to find these eggs, can they be trained to find these eggs while ignoring all these other controls," explains Jennifer Essler, PhD, from the University of Pennsylvania's School of Veterinary Medicine, "as you know, these eggs are normally on trees and cars and we had to make sure that the dogs can really hone in on that."

A new program out of The University of Pennsylvanias School of Veterinary Medicine is training dogs to smell out the Spotted Lanternfly. While the human nose cannot detect the invasive pest, a dogs snout doesnt skip a beat.

"Dogs see the world with their nose just like we see the world with our eyes," Essler tells PBS39, "But the really critical thing about dogs is that they communicate with us. So there are tons of animals in the animal kingdom that have as good, or better, olfactory capabilities as dogs but we need to not only train them to find eggs but to tell us that theyve found the eggs! So thats really the critical point and the relationship that dogs have with humans and their willingness to work with us and cooperate with us really makes them special for these types of tasks."

Beyond causing severe damage to trees and heavily affecting quality of life for humans, experts warn the Spotted Lanternfly poses a serious threat to the states agriculture industry. But UPenn researchers have found that dogs are perfectly capable of sniffing out the insects eggs with extreme accuracy. That is, of course, after rigorous training.

"For the dogs we used in the study, we were very lucky. They were already trained to find odors so they knew the game; find this odor and get a reward whether its a toy or food," Essler says, "So for this task, it started with putting the SLF egg in like a tin on the floor and when they showed any interest or sniffed it, we have a clicker that we use to mark that behavior and they get a reward. Just pairing that odor with that game and increasing it in difficulty like adding in other odors that might, in our mind, trip them up or things they need to learn to ignore, ramping up the game closer and closer to what they would need to do in the real world."

VO4: Penn Vets pilot training program comes at the perfect time. Right now is prime egg laying season for the Spotted Lanternfly and experts say early egg-mass detection through canine surveillance might just be the edge needed to fight the spread of the insect in Pennsylvania.

"They basically have a one year lifespan so all these crazy bugs you see, theyll all die by winter. But what they do leave is their eggs. Their eggs do this process that we call overwintering; so, theyll sit on the trees from now until early spring and then thats when the life cycle starts again and youll start to see those tiny bugs," Essler tells PBS39 News Tonight, "and so this is a really critical time because other than humans or other animals moving these eggs, they are stationary and so it's a good time for researchers and those working with this pest to go in and either access the eggs in an area or make sure they dont leave a quarantine zone."

The program is back up and running after coronavirus put it on pause for a few months, so lanternflies watch out.

Read this article:
How Dogs are Being Trained to Help Fight Off Spotted Lanternfly - PBS39.org

Dublin, Oct. 06, 2020 (GLOBE NEWSWIRE) -- The "Pyrethrin Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type, Pest Types, Application" report has been added to ResearchAndMarkets.com's offering.

According to this report the market was valued at US$ 235.35 million in 2019 and is projected to reach US$ 353.53 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027.The report highlights key factors driving the market growth and prominent players along with their developments in the market.

Pyrethrin are classified as a class of organic compounds which are obtained from chrysanthemum cinerariifolium that can act as effective insecticides by targeting the nervous system of insects. Pyrethrins are treated as an organic insecticide in combination with piperonyl butoxide or other synthetic adjuvants and is known for its insecticidal and insect repellent characteristics features. They are increasingly being used as an effective alternative of organochlorides and organophosphates and are highly preferred to pyrethroids, a synthetic form of pyrethrin which gets accumulated in the environment.

Pyrethrin is widely used in veterinary medicine for agricultural and domestic purposes. It is used for the treatment of ectoparasites in large and small animals and also in non-mammalian species such as birds, fish, and honeybees. It is used in veterinary medicine in various formulations, including spot-on, sprays, ear tags, soluble powders, and dips. Apart from its usage as veterinary medicine, it is also used in treatment of lices and scabies. Also, permethrin cream, prepared from pyrethrin, is often recommended during pregnancy and lactation. Synthetic pyrethroids have been classified into two types: type I and type II. It is observed that the addition of the alpha-cyano group to the 3-phenoxylbenzyl alcohol group in type II has increased the insecticidal potency. Pyrethrin and piperonyl butoxide are used to make a skin and hair shampoo. It is applied twice to thrice to treat lice. Pyrethrin is also used in body lice medicines such as A-200, Pyrinate, Barc, Lice-Enz, Licetrol, Pronto, Tisit, Tisist blue, and Tripple X. The medical applications of pyrethrin are boosting the demand for pyrethrin all across the globe.

The COVID-19 pandemic has been affecting economies and industries in various countries, including the US, Brazil, Russia, India, Italy, the UK, Iran, and Spain. Chemicals and materials is one the world's major industries suffering serious disruptions in the form of supply chain breaks, event cancellations, and office shutdowns as a result of the lockdowns imposed in various countries to contain the disease spread. China is the global manufacturing hub and the largest raw material supplier for various industries; it is also one of the worst-affected countries by the COVID-19 pandemic. The lockdown of various plants and factories in China is affecting the global supply chains and adversely impacting the manufacturing and sales of various chemical and materials. These factors are likely to restrain the growth of various markets related to the chemicals and materials industry in next few financial quarters.

Botanical Resources Australia Pty Ltd; China Xi'an Nutrendhealth Biotechnology Co, Ltd; Endura; Zhejiang Rayfull Chemicals Co.,Ltd.; Pestech Australia Pty Ltd. Scintex; Sumitomo Chemical Co., Ltd. Horizon Sopyrwa; Kapi Limited; and Zhengzhou Delong Chemical Co., Ltd are among the well-established players in the global pyrethrin market.

Reasons to Buy:

Key Topics Covered:

1. Introduction1.1 Study Scope1.2 Research Report Guidance1.3 Market Segmentation

2. Key Takeaways

3. Research Methodology3.1 Scope of the Study3.2 Research Methodology3.2.1 Data Collection:3.2.2 Hypothesis formulation:3.2.3 Macro-economic factor analysis:3.2.4 Developing base number:3.2.5 Data Triangulation:3.2.6 Country level data:

4. Pyrethrin Market Landscape4.1 Market Overview4.2 PEST Analysis4.2.1 North America4.2.2 Europe4.2.3 APAC4.2.4 MEA4.2.5 SAM4.3 Expert Opinion

5. Pyrethrin Market - Key Market Dynamics5.1 Market Drivers5.1.1 Pyrethrin as an organic insecticide favours market growth5.1.2 Medicinal applications of Pyrethrin5.2 Market Restraints5.2.1 Harmful effects of Pyrethrin5.3 Market Opportunities5.3.1 New pyrethrum industry established in Tasmania, Australia for pyrethrin extract5.4 Future Trends5.4.1 Genetic engineering for natural pyrethrin5.5 Impact Analysis Of Drivers And Restraints

6. Pyrethrin - Global Market Analysis6.1 Pyrethrin Market Overview6.2 Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)6.3 Market Positioning - Key Market Players

7. Pyrethrin Market Analysis - By Type7.1 Overview7.2 Pyrethrin Market, By Type (2019 and 2027)7.3 Pyrethrin I7.3.1 Overview7.3.1.1 Pyrethrin I: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)7.4 Pyrethrin II7.4.1 Overview7.4.1.1 Pyrethrin II: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)

8. Pyrethrin Market Analysis - By Pest Type8.1 Overview8.2 Pyrethrin Market, By Pest Type (2019 and 2027)8.3 Lepidoptera8.3.1 Overview8.3.1.1 Lepidoptera : Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.4 Coleoptera8.4.1 Overview8.4.1.1 Coleoptera: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.5 Mites8.5.1 Overview8.5.1.1 Mites: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.6 Diptera8.6.1 Overview8.6.1.1 Diptera: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)8.7 Others8.7.1 Overview8.7.1.1 Others: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)

9. Pyrethrin Market Analysis - By Application9.1 Overview9.2 Pyrethrin Market, By Application (2019 and 2027)9.3 Agricultural Insecticides9.3.1 Overview9.3.1.1 Agricultural Insecticides: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.4 Household Insecticides9.4.1 Overview9.4.1.1 Household Insecticides: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.5 Commercial and Industrial9.5.1 Overview9.5.1.1 Commercial and Industrial: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.6 Animal Healthcare9.6.1 Overview9.6.1.1 Animal healthcare: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)9.7 Others9.7.1 Overview9.7.1.1 Others: Pyrethrin Market -Revenue and Forecast to 2027 (US$ Mn)

10. Pyrethrin Market - Geographic Analysis10.1 Overview10.2 North America: Pyrethrin Market10.3 Europe: Pyrethrin Market10.4 APAC: Pyrethrin Market10.5 MEA: Pyrethrin Market10.6 SAM: Pyrethrin Market

11. Impact of COVID-19 Pandemic on Global Pyrethrin Market11.1 Overview11.2 North America: Impact Assessment of COVID-19 Pandemic11.3 Europe: Impact Assessment of COVID-19 Pandemic11.4 Asia-Pacific: Impact Assessment of COVID-19 Pandemic11.5 Middle East and Africa: Impact Assessment of COVID-19 Pandemic11.6 South America: Impact Assessment of COVID-19 Pandemic

12. Key Company Profiles12.1 Botanical Resources Australia Pty Ltd.12.1.1 Key Facts12.1.2 Business Description12.1.3 Products and Services12.1.4 Financial Overview12.1.5 SWOT Analysis12.2 China Xi'an Nutrendhealth Biotechnology Co., Ltd.12.2.1 Key Facts12.2.2 Business Description12.2.3 Products and Services12.2.4 Financial Overview12.2.5 SWOT Analysis12.3 Endura12.3.1 Key Facts12.3.2 Business Description12.3.3 Products and Services12.3.4 Financial Overview12.3.5 SWOT Analysis12.4 Zhejiang Rayfull Chemicals Co., Ltd.12.4.1 Key Facts12.4.2 Business Description12.4.3 Products and Services12.4.4 Financial Overview12.4.5 SWOT Analysis12.5 Pestech Australia Pty Ltd.12.5.1 Key Facts12.5.2 Business Description12.5.3 Products and Services12.5.4 Financial Overview12.5.5 SWOT Analysis12.6 Scintex12.6.1 Key Facts12.6.2 Business Description12.6.3 Products and Services12.6.4 Financial Overview12.6.5 SWOT Analysis12.7 Sumitomo Chemical Co., Ltd12.7.1 Key Facts12.7.2 Business Description12.7.3 Products and Services12.7.4 Financial Overview12.7.5 SWOT Analysis12.8 Horizon Sopyrwa12.8.1 Key Facts12.8.2 Business Description12.8.3 Products and Services12.8.4 Financial Overview12.8.5 SWOT Analysis12.9 Kapi Limited12.9.1 Key Facts12.9.2 Business Description12.9.3 Products and Services12.9.4 Financial Overview12.9.5 SWOT Analysis12.10 Zhengzhou Delong Chemical Co., Ltd12.10.1 Key Facts12.10.2 Business Description12.10.3 Products and Services12.10.4 Financial Overview12.10.5 SWOT Analysis

13. Appendix13.1 About the Publisher13.2 Glossary

For more information about this report visit https://www.researchandmarkets.com/r/3lgajp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more:
Worldwide Pyrethrin Industry (2020 to 2027) - by Type, Pest Types, and Application - GlobeNewswire

Pet adoptions have significantly increased during COVID-19

They are cute, they are cuddly, they are a comfort especially in a pandemic, a time many people feel socially isolated and when distractions are welcome.

Updated: 8:31 PM EDT Oct 6, 2020

Hide TranscriptShow Transcript

THAT WAS GOOD NEWS LOOKING -- FOR ANIMALS LOOKING FOR A PERMANENT HOME. >> IT HAS ACTUALLY BEEN REALLY FUN TO HAVE A DOG. WHAT ALSO YOU SUPPOSED TO DO? >> THEY ARE CUTE AND CUDDLY AND THE COMFORT. ESPECIALLY GET A PANDEMIC, A TIME MANY FEEL SOCIALLY ISOLATED AND WHEN DISTRACTIONS ARE WELCOME. >> I GOT JET IN APRIL. I WOULD HAVE BEEN BORED WITHOUT HIM. >> CASINO ALWAYS JOINED BEING A DOGMA WITH TIME ON HER HANDS, COVID PROVIDED THE OPPORTUNITY. >> I GOT LAID OFF. I HAD SO MUCH TIME AND WAS LIKE GOING TO DO IT. >> THE STRASBURGER FAMILY ALSO CONSIDERED A PUPPY BUT TOOK AN UNUSUAL APPROACH IN ADOPTING THEIR POOCH. >> WE KNEW WE WANTED A DOG THAT COULD RUN AROUND ALL DAY AND WHO WAS ALSO BIG ENOUGH NOT TO GET HURT IF THEY ARE TUMBLING AROUND. WITHOUT ADOPTING A DOG FROM A SERVICE TO BE A PERFECT THING. >> DID YOU HAVE ANY HESITATION ABOUT ADOPTING A DOG IN A NEARBY PANDEMIC? >> WE KNEW WE WOULDNT BE COMPLETE WITHOUT A DOG AT HOME. ASK THE PANDEMIC HAS HAD A MAJOR IMPACT ON OUR LIVES, INCLUDING THE ADDITION OF MORE ANIMALS. PET ADOPTIONS ARE UP AROUND THE COUNTRY. 80% OF PETS AND SHELTERS THAT REPORT THEIR DATA WERE ADOPTED, AN INCREASE OVER THE SAME TIME IN 2019. >> THE MS PCA HAS TAKEN IN 21 HUNDRED ANIMALS THE PANDEMIC HIT IN MARCH WHICH THEY SAY IS ABOUT TYPICAL, BUT ADOPTIONS ARE UP ABOUT 20% OVER THE SAME TIME. >> ANY TIME WE HAVE AN ANIMAL THAT IS AVAILABLE, THEYRE GETTING LOTS OF INTEREST AND THEY ARE GOING QUICKLY AND THE LENGTH OF STAY IS DOWN. >> MIKE IS DIRECTOR OF ADOPTION CENTERS AND PROGRAMS. >> WE ARE SEEING A LOT OF PEOPLE MOTIVATED TO TAKE AN ANIMAL ON. PEOPLE ARE WORKING FROM HOME AND THEM THE OPPORTUNITY TO INTRODUCE AN ANIMAL BETTER. WE PIVOTED QUICKLY ON THAT START DOING FACEBOOK LIVE AND BUILT THAT OPPORTUNITY FOR PEOPLE TO CONNECT WITH AN ANIMAL. >> DOGS ARE IN DEMAND BUT SO ARE OTHER FURRY FRIENDS. >> I FEEL LIKE RABBITS DONT GET ENOUGH CREDIT. MOST KNOW THEM FOR BEING IN SMALL CAGES BUT THEY COULD HAVE AS MUCH PERSONALITY AS A DOG OR CAT. THEY CAN BE CALLED AND STRAINED THIS IT WITH YOU ON THE COUCH AND WATCH TV. >> HE SAYS CATS MAKE PERFECT COMPANIONS AND ARE LOOKING FOR FUR-EVER HOMES. >> PEOPLE THINK CATS ARE INDEPENDENT BUT THIS GUYS MORE AFFECTIONATE THAN ANY DOG I HAVE EVER MET. THIS IS THE TYPE OF CAP THAT WANTS TO BE IN A HOME ND NOT A SHELTER. AND YES EVEN CARE THAT WE ARE WEARING MASKS AND LOOK WEIRD RIGHT NOW. >> IN THIS -- AN ASSISTANT PROFESSOR SAYS ANIMALS ARE ABLE TO HELP HUMANS THROUGH STRESSFUL TIMES LIKE THESE NO MATTER THE SIZE, SHAPE OR SPECIES. >> A LOT OF WHAT WE KNOW ABOUT THE SCIENCE OF PET OWNERSHIP IS THAT PEOPLE REALLY TURN TO THEIR PETS AS A SOURCE OF EMOTIONAL SUPPORT. PARTICULARLY WHEN THEY FEEL STRESSED AND AS A NONJUDGMENTAL COMPANION. I THINK THAT DURING THE PANDEMIC, WE ARE NOT ONLY EXPERIENCING A LOT OF STRESS BUT ALSO ISOLATED FROM OTHER PEOPLE WHO MIGHT BE OUR EMOTIONAL WORK AND THATS WHY PETS ARE SO IMPORTANT. >> BROADWAY IS FITTING RIGHT IN AND HAS BECOME MORE THAN A PET. >> HES PART OF THE FAMILY AND HE HAD SO MUCH VALUE >> A MATCH MADE IN HEAVEN, HE IS SUCH A GOOD BOY. >> BROADWAY WAS ADOPTED FROM A NONPROFIT RINSE THE MASK THE TRAINED SERVICE DOGS. HE DIDNT MAKE IT IS A SERVICE DOG BUT NOT BECAUSE HE WAS A BAD STUDENT BECAUSE HE HAD MEDICAL ISSUES. HOUSING INSECURITY IS ONE REASON PEOPLE SURRENDER PETS THEY BELIEVE A TEMPORARY MORATORIUM ON CLOSURES AND EVICTIONS HELP BUT DOES EXPECT A SURGEON INTAKE WHEN THEY EVENTUALLY RESUME.

Pet adoptions have significantly increased during COVID-19

They are cute, they are cuddly, they are a comfort especially in a pandemic, a time many people feel socially isolated and when distractions are welcome.

Updated: 8:31 PM EDT Oct 6, 2020

No matter the size, shape or species, Dr. Megan Mueller, an assistant professor of human animal interaction at Tufts Cummings School of Veterinary Medicine, says animals are able to help humans through stressful times like these.The MSPCA has taken in 2,100 animals since the pandemic hit in March, which they say is about typical. However, adoptions are up about 20% over the same period in 2019. When the Strasburger family decided to adopt a dog, they decided adopting from a service dog organization was the way to go.

No matter the size, shape or species, Dr. Megan Mueller, an assistant professor of human animal interaction at Tufts Cummings School of Veterinary Medicine, says animals are able to help humans through stressful times like these.

The MSPCA has taken in 2,100 animals since the pandemic hit in March, which they say is about typical. However, adoptions are up about 20% over the same period in 2019.

When the Strasburger family decided to adopt a dog, they decided adopting from a service dog organization was the way to go.

Original post:
Pet adoptions have significantly increased during COVID-19 - WCVB Boston

The basic principles of homeopathy, and its legal and scientific foundations, are discussed in an overview to address the positions of the World Health Organization (WHO) and the commission of the European Union (EU) on complementary medicine. According to the WHO,the antimicrobial resistance problem poses aglobal threat. The EU Commissions current One Health Action Plan requests research in complementary medicine, the WHO urges member states to include complementary medicine in their national health policies. Regarding external evidence on the general use of human and veterinary homeopathy, evidence level 1a studies are reviewed. Focusing on the external evidence on the use of homeopathy in infections, some evidence level 1a, 1b, 2c studies, and a case report, are described in more detail. In conclusion, evidence for the effectiveness of human and veterinary homeopathy in general, and in particular, of homeopathic treatment for infections, is available. Especially, individualized homeopathy demonstrates effects at all quality levels according to Cochrane criteria, even in the methodologically high-quality studies. As in most areas of veterinary medicine and medicine, further good/excellent studies are necessary. In compliance with the principles of homeopathy, further methodologically high-quality trials focusing on the homeopathic treatment of infections are the next logical step. The selection of the simile (individually fitting homeopathic medicinal product) by appropriately trained homeopathic doctors/veterinarians is essential for the effectiveness of homeopathy. Implementation of studies at university facilities is a prerequisite for quality assurance.Consequently, further integration of homeopathy at universities is a necessary requirement for the patientsbest interests.

PubMed

Link:
[Evidence-based homeopathy and veterinary homeopathy, and its potential to help overcome the anti-microbial resistance problem an overview]. -...

File image.

What are the signs of colic, and what should you do, are among the questions that will be answered in the latest free horse care webinar from World Horse Welfare.

Understanding colic what we as owners need to know at 7pm (GMT) on Wednesday October 7, is being hosted byDr Katie Lightfoot, a Teaching Associate at the University of Nottinghams School of Veterinary Medicine and Science joins World Horse Welfares International Programme Officer Izzy Wild, who is also a vet, and has experience of dealing with complex colic case.

The webinar is part of the charitys Welfare Wednesday series that runs fortnightly.

Katie will explain what owners can do to prepare themselves if their horse gets colic. She will discuss the types of decisions owners may have to make and provide some real-life case studies of owner experiences. Izzy will explain what the main risk factors are and talk through the critical signs owners should be able to recognise and what steps to take.

Both will answer questions at the end of the webinar, and both are keen to share their experiences to ensure owners we are as informed as possible about what happens if their horse gets colic.

The fortnightly webinars are free to attend and they can also be viewed live as a Facebook Live session, but by registering with Zoom you get to take part in the various polls, ask questions during the Q&A and overall have a much more interactive experience.

Register here

About the presenters:

Dr Katie Lightfoot is a Teaching Associate at the University of Nottinghams School of Veterinary Medicine and Science. As part of the equine teaching team, she supports the learning of undergraduate vet students in subjects such as equine welfare, anatomy, and behaviour. Before joining the university, Katie completed a PhD research project which evaluated horse owner behaviour and knowledge transfer in response to an educational campaign.

Izzy Wild graduated from the University of Nottingham as a vet, also undertaking a Research Masters with the Nottingham Colic Project. Following finals, she researched colic in working equids in Honduras at a World Horse Welfare partner-project. She worked in First Opinion equine practice for two years in Hampshire, before joining World Horse Welfare in August, where she is working as an International Programme Officer. Izzy has an interest in veterinary research, education and working equids.

All previous webinars are available to watch on the World Horse Welfare YouTube channel.

xx

Read more:
Free webinar: What horse owners need to know about colic - Horsetalk

When Jeff Pleiss, associate professor of molecular biology and genetics in the College of Arts and Sciences, began studying RNA biology two decades ago, he could not have known that the kind of high-volume RNA analysis his lab performs on single-cell yeast would have any importance in fighting a pandemic.

Pleiss studies rare RNA species in different, changing environments, elucidating pathways in RNA biology that are critical for gene expression in eukaryotes. To do this, he must take cellular mixes and robustly and carefully separate RNA in order to identify different RNA species. Identifying COVID-19 in humans requires similar separation of RNA.

The Cornell COVID-19 Testing Lab, housed in the College of Veterinary Medicines Animal Health Diagnostic Center, had been handling thousands of clinical samples from animals a day. Beginning in August, it adapted and expanded routine testing for COVID-19.

In a typical day, Pleiss lab examines up to 20,000 specimens at a time. When Cornell was faced with the challenge of developing its own testing system, Pleiss stepped forward to offer his labs experience with RNA processing. They use a robotic process to pool specimens to achieve such a high volume. The Cornell COVID-19 Testing Laboratory (CCTL) acquired similar robots, and the Pleiss lab Ph.D. candidate Zach Dwyer helped to write the scripts for the liquid handlers to prepare sample pools.

CCTL is housed in and led by the College of Veterinary Medicines Animal Health Diagnostic Center (AHDC). The AHDC had been handling thousands of clinical samples from animals a day and now was adapting and expanding their routine testing for COVID-19. As a Level 1 laboratory of the National Animal Health Laboratory Network (NAHLN) the center was set up to test 800 to 1,200 samples for animal infectious diseases in one work shift; using robotic liquid handlers with Pleiss input now facilitated the processing of 5,000 to 7,000 tests a day.

Members of the Pleiss lab, which like the AHDC and CCTL use a 96-well format and similar equipment, are looking for ways to further streamline and enhance efficiencies of CCTLs critical work by investigating the possibility of testing larger pools.

The Pleiss lab also has experience using standard, off-the-shelf components for the testing process rather than more expensive commercial kits, which enables them to achieve their high volume of testing in an affordable way. And commercial kits can be subject to global supply limitations, Pleiss said, adding that such kits are like pre-made chocolate chip cookie dough.

Pre-made dough is easy to make into cookies, but package availability may be limited, he said. Sugar and flour and eggs, though, are almost always available, so youll never run out of the components.

With high-volume testing underway at CCTL, Pleiss and his students continue to explore ways that their expertise can support Cornells COVID-19 testing system.

Jeffs lab illustrates how researchers from different fields have mobilized to support Cornell through this pandemic, and how scientists doing foundational, curiosity-driven research can make meaningful contributions to applied problems, said Andrew Bass, the Horace White Professor of Neurobiology and Behavior and senior associate dean in Arts and Sciences.

We are working in parallel with CCTL, staying out of their way while looking for ways to optimize what theyre doing, Pleiss said. The goal is to getthroughput higher and costs even lower, all withoutsacrificing sensitivity.

Kate Blackwood is a writer for the College of Arts and Sciences.

Follow this link:
RNA analysis at heart of COVID-19 testing | Cornell Chronicle - Cornell Chronicle

In the final months before the coronavirus changed all of our lives, Whitwell High School sophomore Grace Moore won three age-group state archery championships in three different states. Known as Grace-E to many of her friends and family, it's only a rumor that the "E" stands for Extraordinary. In truth, her middle name is Elizabeth, hence the "E."

But as amazing as those championships were, as blindingly bright as her future may be in competitive archery, bows and arrows are far from the most extraordinary part of the 15-year-old's story.

"She was six years old," recalled Grace's mother Alison on Monday night. "The doctor told us that without surgery, the Grace we see would not be the Grace we'd keep."

The option the surgeon was offering Jimmy and Alison Moore to rectify Chiari Malformations a rare birth defect where portions of the brain, the cerebellar tonsils, protrude through the bottom opening of the skull into the upper spine, causing pressure on the brain or spinal cord would terrify any parent.

Brain surgery was required. Shaving vertebrae. Removing tissue from the crown of Grace's head to serve as a patch for her brain.

"I'm a nurse, had been for 18 years," said Alison. "And I'd never heard of this. You're told your child has something wrong with their brain and spinal cord. You're terrified."

The seizures started on the 21st day of December in 2011. Grace's speech would be garbled for a few seconds, then return to normal. The first guess by doctors was that she might be having a reaction to some cold medicine. The Moores stopped the medicine. The seizures continued.

"We went to Children's Hospital on Christmas Eve," Alison said. "They did a CT scan that was negative for a brain tumor. We felt better."

But a few days after Christmas they went back for an MRI. She was to be in the machine for 40 to 45 minutes. Medical personnel came back after that time and told Alison and Jimmy they needed 40 minutes more.

"That's when I realized this was serious," said Alison.

It was so serious that the doctor who would ultimately operate on Grace at the Alabama-Birmingham Medical Center, renowned surgeon Jerry Oakes, warned the Moores that there could be dire consequences.

"He told us that Grace could have a stroke, bleed to death, become paralyzed," remembered Alison.

But as they debated the risks, they finally came around to one indisputable fact: "We couldn't bear the thought," said Alison, "that we didn't give her a chance to live a normal life."

So Oakes operated, telling the family the procedure would take 82 minutes. Sure enough, after 82 minutes, he emerged with a bag of Grace's shaved hair, including her ponytail, to let the Moores know all had gone well.

Still, there would be six weeks of rehab and healing at home, with the following instructions from Oakes: "No boxing, no football, no wrestling."

Added Alison: "Mom's restrictions were a little longer."

But for a 6-year-old girl whose older brother Tyler was active in athletics, being banned from contact sports such as softball, volleyball and the like was a major adjustment.

Said Grace: "We're an active family. I wanted to be active, too."

Enter the Marion County 4-H club, which introduced her to archery.

"I picked it up right off the bat," she said. "It's pretty much my life now."

Said Jody Castle, who was the first person to work with Grace through his Castle Outdoors shop in Whitwell: "A normal person will come to my archery range and shoot 12-15 shots. Grace won't quit until she's shot at least 150 to 200 arrows. I've seen her come here and shoot 500 shots over four or five hours. She's just got a passion for it. And she hits the bullseye almost every time."

How passionate has she become on her way to winning Middle School state titles in Georgia, Kentucky and Tennessee, as well as being ranked sixth in her age group nationally?

A few years ago, on the way to her 8th grade winter dance, Grace stopped at Castle's store to shoot a 100 or so arrows. She was already wearing her dress and heels.

"Archery is Grace's platform, her ministry," said Alison. "She's as comfortable around a 5-year-old as a 75-year-old when she's discussing archery. You can just see her glow."

Grace says that glow began about the time she picked up the sport and Tyler now 22 and wrapping up his pre-veterinary medicine degree at the University of Tennessee Knoxville graduated from Whitwell High.

"Tyler always made good grades and was good in sports," Grace said. "When Tyler left, that was my time to flourish. I started making straight A's and winning archery contests."

No one knows where any of this will lead. Her work with 4-H has made her a national shooting sports ambassador. Her archery talents with both the Marion County 4-H team and the Harvest Archery squad in Dayton, Tenn., continue to move her up the national rankings. If her pre-match meals of cheese fries and lemonade keep doing the trick, she may even turn pro at some point.

Maybe then she could pay her parents back for the cost of those four "Robin Hoods" she's collected. For non-archery buffs, a Robin Hood is when you shoot an arrow into the back of another arrow.

"When Grace was starting out, that was fine," said Alison. "Everybody was impressed. But once she got better and those arrows started costing $20 each, I told her that I thought we'd bought enough $40 trophies."

But for Alison, the most priceless moment of the last nine years, a moment that brings the good and the bad of that time full-circle, centers on Tyler, who began riding his bike and distance running as Grace was dealing with her medical issues.

"That was his coping mechanism," said Grace.

All this training eventually led to an Iron Kids event at Harrison Bay State Park, which Tyler won.

"I looked at his time," said Alison. "It was 82 minutes. I said to myself, 'God took care of both of my kids in 82 minutes."

Contact Mark Wiedmer at mwiedmer@timesfreepress.com.

Read the original post:
Wiedmer: Whitwell's Grace Moore doesn't need her bow and arrow to hit your heart - Chattanooga Times Free Press

By Dylan Adams News Editor

Timothy Ray Brown, the first known person to be cured of HIV, died on Sept. 29 at age 54 after battling cancer.

Timothy Ray Brown, a figurehead in the AIDS and HIV community, passed away surrounded by friends after a five-month battle with leukemia, stated Tim Hoeffgen, Browns partner.

Brown received a positive HIV diagnosis in 1995 while studying in Berlin.

In 2006, Brown was diagnosed with acute myeloid leukemia, which is a cancer that builds in the bone marrow and blood interfering with blood cell production. After bouts of infections from several rough rounds of chemotherapy, Browns leukemia came out of remission.

Due to leukemia in his bones, Brown required a stem cell transplant, a process that allows healthy stem cells to be introduced into a host to stimulate the immune system and healthy bone marrow growth. At the time, the survival rates for stem cell transplant were around fifty percent.

Doctors found a match to Browns genetic type, a donor with the CCR5 Delta 32 mutation, a protein that acts as a doorway to stop the HIV from infecting new cells. Three months after Brown stopped taking his HIV medication, doctors found he no longer had HIV in his blood.

After another round of stem cell treatment in February of 2008, Brown went through several near-death complications, almost going blind and becoming paralyzed but slowly recovering. His body was still successfully fighting off HIV.

In July 2012, the Timothy Ray Brown Foundation was created during the World AIDS Conference in Washington, DC. This foundation was built for Brown to show his support and work with medical institutions and scientists to develop a unifying cure and vaccination against HIV.

Brown would often donate large amounts of blood and tissue samples to researchers in the hope of progressing closer towards an HIV cure. According to his partner, Hoeffgen, Tims lifework was to tell his story about his HIV cure and become an ambassador of hope to those in need.

Doctors have since used Brown as a blueprint to work on a potential cure and vaccine for HIV. Most notably for the second person to ever be cured of HIV the London Patient, Adam Castillejo who went through similar stem cell transplants in 2019 before coming forward to the public.

Like Loading...

Related

Read the rest here:
First Man Cured of AIDS Dies From Cancer - The Keystone Newspaper

In 2004, after President George W. Bush cut off all federal funding for embryonic stem-cell research on religious grounds, Californians strongly backed Proposition 71, a $3-billion bond measure to fund this kind of research, even though such funding is usually not the purview of states.

Supporters of the proposition including this editorial board believed it would allow California to stand out as a leader in this field, advance a budding avenue of research that might save lives and alleviate suffering, bolster its biotech sector and fund possible blockbuster treatments that might earn the state royalties as well. Embryonic stem cells are particularly valuable to research because they are undifferentiated, meaning they do not have a particular function, and researchers could conceivably turn them into specialized cells in order to regenerate human cells and tissue.

In the years since, Proposition 71 gave rise to a burst of scientific discovery. Two cancer treatments it helped fund, for blood and bone-marrow cancers, have been approved by the FDA, though neither of those employed embryonic stem cells and could have been funded even under Bush administration rules. It has also supported promising advances in the treatment of diabetes, bubble boy immune deficiency and vision-robbing retinitis pigmentosa, but other efforts have fallen short in clinical trials.

Moreover, the money helped build laboratories and other infrastructure that give California a head start on research and development, making the state the it place for stem-cell research. Researchers in the state moved to the head of the pack for private grants, because projects are less likely to need the time and money to create facilities before work can begin.

Now that Proposition 71 funding has practically run out, the issue is back on the November ballot with Proposition 14, which seeks nearly double the amount worth of bonds $5.5 billion to continue the juggernaut.

This time, voters should reject the measure, with the caveat that the issue could be reconsidered in a couple of years, if its proponents bring it back in better-designed and more modest form and if there are more successes in human trials and financial payback.

We have long had reservations about how the California Institute for Regenerative Medicine, established as a result of Proposition 71, was set up. Though funded publicly, it is not overseen by the governor and Legislature like other state agencies, and its governing board is too large, at 29 members. Those members generally have ties to the advocacy organizations and research institutions that have received most of the money.

The driving force behind the initiative has been Robert N. Klein II, a Bay Area lawyer and real estate investor. There is no doubting Kleins sincerity in his cause. He knows too well the suffering inflicted by intractable diseases; his son Jordan died of complications of Type I diabetes in 2016. His accomplishment in persuading the state to invest billions in a specific avenue of biomedical research has been exceptional.

However, Klein developed these initiatives largely behind closed doors with little to no public input; he has strong ideas about how things should be run on the stem-cell front and has steadfastly resisted more government oversight. Thats fine when hes investing his own money; its a fatal flaw when he is asking voters for nearly $8 billion, the estimated cost of paying off the bonds over time, according to the Legislative Analysts Office.

Kleins role and the bloated structure of CIRMs super-sized governing board have given rise to some serious ethical mishaps, including a board member who improperly intervened to try to get funding for his organization. (He is no longer on the board.) After this and several other examples of impropriety, rules were tightened. Board members must recuse themselves from votes when there is a conflict of interest, but with 29 members who all want certain projects to receive funding, there is too much potential for mutual back-scratching. Instead of repairing this problem, the new proposition would expand CIRMs board to 35 members and retain its troubling independence from oversight by the governor and Legislature, leaving it open to further conflicts of interest.

Proposition 71 hasnt yet yielded a significant financial return on investment for the state or the cures that were ballyhooed at the time. Though no one ever promised quick medical miracles, campaign ads strongly implied they were around the corner if only the funding came through. Proponents oversold the initiatives and voters cant be blamed if they view this new proposal with skepticism.

In the years since Proposition 71 passed, more resources have become available. President Obama reversed Bushs order and restored federal funding, which meant that between CIRM and the National Institutes of Health, along with private grant and investment funding, stem-cell research has been healthy, if not downright flush. That funding has stayed and even grown under President Trump, to more than $2 billion a year, with about $321 million of that in human embryonic stem-cell research. (There have, though, been recent threats to embryonic research from a group of conservative senators.)

The idea was never for California to become the long-term replacement for federal funding. It was to kick-start an industry that would then operate on its own. If that has failed to happen under Proposition 71 as promised, it shouldnt be the responsibility of California taxpayers to fix it. Thats especially true right now, at a time of yawning needs to address the cost of twin health and economic crises and the worsening effects of climate change. Private money for stem cell-work will continue to be available; its not as though research will collapse.

No doubt, the pace of responsible science is incremental and the outcomes uncertain even with the best research efforts. Yet the backers still couch the possibilities in grandiose terms. In a recent interview with the Times editorial board, Klein talked about the money that would be saved by wiping out Alzheimers disease which has so far has frustrated attempts to treat it effectively, despite many billions of dollars in research.

Embryonic stem cell research remains important, and there might be ways in which the state can contribute less grandiose funding while maximizing its investment. For example, scientific research has a well-known valley of death, where many projects cant get funding to make the transition from laboratory to human clinical trials.

Offering some matching help to get projects through that phase might attract businesses and scientists to California, while spending far less than the billions proposed in Proposition 14. Its worth noting that stem-cell work isnt the only kind of research that faces the valley of death problem; its an issue for most basic research that seeks to make the leap to human trials and that might be equally in need of state help.

Now is not the time for a huge new investment in specialized medical research. First, it makes sense to wait until after the election; if Democrats do well, there should be growing support for embryonic stem-cell research at the federal level, which is where such funding should take place. The future of Californias pandemic-battered economy and budget remains to be seen. Waiting also would give voters a chance to find out how well the states stem-cell research projects continue without state dollars, and whether some of the promising advances lead to breakthrough therapies and a return on Californias investment.

There would be an opportunity to rethink and rewrite any future proposals, which should include a far more modest ask of taxpayers as well as fixes to the structure and inflated size of the CIRM board. The institute should also be placed under the same state oversight as other agencies reporting to the governor.

If CIRM needs money for a basic operating budget over the next couple of years, that could be covered by the states general fund. The agency still needs to administer already-funded projects and could use that time to discuss a more affordable path forward. Right now, the state has other, more urgent spending priorities.

Editors note: This newspapers owner, the physician and scientist Dr. Patrick Soon-Shiong, played no role in the editorial boards deliberations on this measure.

See original here:
No on Prop 14: Not the best way to support stem-cell research - Los Angeles Times

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector.

The influence of animal stem cell therapy for the treatment of various animals for diverse diseases and disorders is growing rapidly. Therefore, this factor may help the global animal stem cell therapy market to generate exponential growth across the forecast period of 2019-2029. Stem cells help in the replacement of neurons affected by stroke, Parkinsons disease, spinal cord injury, Alzheimers disease, and others.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6816

This animal stem cell therapy market report has extensive information on various aspects associated with bringing growth. Important factors such as emerging trends, mergers and acquisitions, and the regional scenario of the animal stem cell therapy market have been analyzed and included in the report. The stakeholders can derive a treasure of information from this report. This report also includes a scrutinized take on the COVID-19 impact on the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Competitive Prospects

The competitive landscape of the animal stem cell therapy market can be described as mildly fragmented. With a considerable chunk of players, the animal stem cell therapy market is surrounded by substantial competition. Research and development activities form an important part of the growth landscape because they help gain novel insights.

Activities such as mergers, acquisitions, joint ventures, collaborations, and partnerships form the foundation of the growth of the animal stem cell therapy market. These activities help manufacturers to gain influence and eventually help in increasing the growth rate of the animal stem cell therapy market. Prominent participants in the animal stem cell therapy market are Magellan Stem Cells, Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc., Celavet Inc., VETSTEM BIOPHARMA, and VetCell Therapeutics.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6816&ltype=S

Animal Stem Cell Therapy Market: Key Trends

Infections are scaling up among animals at a rapid rate. The alarming increase is proving fatal for many animals. Therefore, to avoid such incidences and treat existing diseases and disorders, animal stem cell therapy is being applied seamlessly. Hence, this aspect may bring great growth opportunities for the animal stem cell therapy market.

Developments have been observed across the animal stem cell therapy market for long. Autologous adipose-derived mesenchymal stem cells are gaining traction for successfully resolving a range of issues in animals. These stem cells help in treating ligament and tendon injuries to a certain extent. The strengthening influence of this stem cell type in companion animals is also proving to be a prominent growth prospect for the animal stem cell therapy market.

Recent research has also found that stem cell-derived CC exosomes showed improved recovery from myocardial infarction (MI) among pigs. Such developments assure promising growth for the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Regional Analysis

The animal stem cell therapy market is spread across North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The animal stem cell therapy market may derive significant growth from North America. The escalating awareness regarding animal stem cell therapy may attract profound growth. Strengthening research and development activities in the region regarding animal stem cell therapy is further expanding the growth prospects.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6816

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read more from the original source:
Animal Stem Cell Therapy Market - Great Growth Opportunities for the Market in the Coming Year | TMR Research Study - BioSpace

The FDA has issued (PDF) a complete response letter to Mesoblasts request for approval of allogeneic cell therapy remestemcel-L in children with steroid-resistant graft-versus-host disease. FDA officials want to see data from at least one additional clinical trial before granting full authorization, but Mesoblast is still hoping to snag an accelerated approval using its existing data.

Evidence of the FDAs concerns with Mesoblasts remestemcel-L filing emerged in August when the agency released a briefing document to inform a discussion of the application by the Oncologic Drugs Advisory Committee (ODAC). The FDA cited multiple perceived shortcomings of the filing, arguing for example that the ability of the mesenchymal stem cell therapy to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated.

Despite the FDAs concerns, ODAC members voted nine to one that the data support the efficacy of remestemcel-L in children with steroid-resistant graft-versus-host disease. The positive ODAC vote sent shares in Mesoblast, which had been depressed by the briefing document, up 50%.

Inside the COVID-SeroIndex Assay Design and Performance

Join a panel of experts as they discuss the rigor involved in optimizing and scaling a reproducible serological assay for COVID-19.

However, the ODAC vote was advisory, and the FDA, in a rare but far from unprecedented action, has chosen to go against the recommendation of the committee. Shares in Mesoblast fell 37% in response to the rejection, sinking back to the low they hit in the wake of the briefing document.

Mesoblast said the FDA has recommended it runs at least one additional randomized clinical trial in adults or children with steroid-resistant graft-versus-host disease before refiling for approval. The recommendation suggests Mesoblast will need to expend time and money to get remestemcel-L to market. The phase 3 trial cited in the briefing document lasted almost three years.

However, Mesoblast is holding out hope that it can get remestemcel-L to some patients without the extra data requested by the FDA. In light of the unmet medical need, Mesoblast plans to request a Type A meeting with FDA to discuss the possibility of an accelerated approval. Mesoblast is hoping the FDA will agree to authorize remestemcel-L on the proviso that it runs a study post-approval.

If Mesoblast is to persuade the FDA to grant remestemcel-L accelerated approval, it may need to address some of the agencys other concerns. Mesoblast said the FDAs response letter identified the need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

The comment reflects sections of the briefing document in which the FDA said the quality attributes lack a demonstrated relationship to the clinical performance of specific [drug product] lots. In the absence of evidence of that relationship, the FDA said the attributes may not be sufficient to ensure the manufacturing process consistently produces remestemcel-L lots of acceptable quality.

In disclosing the response letter, Mesoblast said assays measuring the potency of remestemcel-L will continue to be refined to provide further scientific rationale for its use in severe inflammatory diseases with high mortality risk.

Read this article:
Mesoblast hit by FDA rejection, request to run another trial - FierceBiotech

The current report on Stem Cell Therapy Market covers a comprehensive analysis demonstrating actionable insights for clients. In addition, the report offers business insights that encourage them to take suitable decisions which are likely to leverage their business processes. Moreover, the report is a detailed study exhibiting current market trends with an overview of future market study.

Request Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=15608

Some of the players in the Stem Cell Therapy market include:

Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

PrecisionBusinessInsights has recently launched a latest report on Stem Cell Therapy Market for its clients. This report offers the clients with factual data validated by industry experts and business heads. The report highly involves chapter wise explanation for every aspect of the market wherein the drivers, trends, opportunities, leading and trending segments are discussed in detail with specific examples. Profiles of leading players are also discussed along with their business expansion strategies.

An overview of the Stem Cell Therapy Market report offers a comprehensive analysis for better reference to understand market competition and analysis throughout the forecast period. It also involves key players and their market performance and current developments. It helps you understand the technical jargons that offer ease and convenience to you in understanding the report contents.

RequestCustomization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=15608

Geographical markets are covered separately within the report that includes a competitive analysis on their market performance in the base year as well as predictions for the forecast year. Extensive primary research is conducted to carry out leading information in order to understand the market condition and competition within a specified geography. Comparison between two or multiple geographical markets is carried out effectively to know where to invest in.

Key Features of the Report:

What is the Impact of Covid-19 Outbreak on the Stem Cell Therapy?

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

See original here:
Stem Cell Therapy Market to Show Incredible Growth by 2025 - The Daily Chronicle